Mode
Text Size
Log in / Sign up
N/A N=20 Basic Science

Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes

Prediabetic State

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcome: Primary: Plasma Ketone Concentrations — -52; 12; 493; 627 (µmol/h)/L

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
MCT (Dietary_supplement); MCT+ aerobic exercise (Dietary_supplement); Aerobic exercise (Dietary_supplement); Control day (Dietary_supplement)
Age
Adult, Older Adult · 60+ yrs
Sex
Female
Sponsor
Université de Sherbrooke
Primary completion
Sep 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Plasma Ketone Concentrations
-52; 12; 493; 627; 122; 23
SECONDARY
Plasma Glucose Concentrations
7.6; 11.0; 7.3; 11.6; 7.6; 10.4
SECONDARY
Plasma Triglyceride Concentrations
3.6; 3.8; 3.9; 3.5; 4.0; 3.7
SECONDARY
Plasma Free Fatty Acid Concentrations
1.3; 1.3; 1.3; 1.5; 1.3; 1.4
SECONDARY
Plasma Insulin Concentrations
0.9; 0.8; 0.8; 0.8; 0.8; 0.7

Summary

The aim of this study is to compare the effect on ketone production of dietary an MCT supplement combined or not with physical exercise in two groups of women (N=10/group), healthy adults and patients with prediabetes. After an evaluation of the metabolism (a 4-hour visit with multiple blood samples) at the beginning of the study, all the participants are taken for one-week the MCT supplement alone follow by a one-week period of taking the MCT supplement in combination with physical exercise. At the end of each period of time, the 4-hour visit for the evaluation of the metabolism is repeated.

Eligibility Criteria

Inclusion Criteria

  • Healthy women group: fasting blood glucose < 6.1 mmol/L and HbA1c < 6.0 %.
  • Women with prediabetes: fasting blood glucose between 6.1 and 6.9 mmol/L and HbA1c between 6.0 and 6.4 %

Exclusion Criteria

  • Structured physical activity (more than 2 times per week)
  • Inability to practice physical exercise
  • Diabetes (fasting glucose ≥ 7.0mmol/L or HbA1c ≥ 6.5%)
  • Uncontrolled dyslipidemia or hypertension
  • Use of medications known to affect the metabolism of lipids and carbohydrates (steroids, beta-blockers, diuretics, insulin sensitizers, etc.)
  • Severe infections or inflammations
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02678390). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search